Abstract 1117P
Background
Skin melanoma, particularly acral melanoma, is known for its poor prognosis, often exacerbated by infections and chronic ulcers. Recent research has highlighted the significant role of intratumoral microbiota in various cancers, but its impact remains less understood in Chinese patients with skin melanoma. This study aims to investigate the intratumoral microbiota in melanoma among this group and explore its potential influence on disease progression.
Methods
One hundred melanoma tissue samples from stage III/IV skin or acral melanoma patients at Sun Yat-sen University Cancer Center, collected between 2015 and 2021, were retrospectively collected and underwent LPS immunohistochemistry (IHC). Kaplan-Meier analysis was used to assess the relation of LPS expression and patients overall survival. Microbial diversity was analyzed through 16S rRNA sequencing. Spatial transcriptomics was applied to map LPS-positive and LPS-negative regions, enabling the exploration of transcriptional differences and cell distributions.
Results
Patients with high LPS levels exhibited a median overall survival (mOS) of 13.7 months (95% CI, 10.6–16.9), which was shorter compared to those with low LPS levels, who had not yet reached median survival. Analysis of tumor microbiota revealed significant diversity, with high proportions of Bifidobacterium, Vibrio, Bacillus, Clostridium sensu stricto, and Pseudomonas, among which Pseudomonas was the dominant genus. Spatial transcriptomic analysis of LPS-positive melanoma tissues showed an increased proportion of M2 macrophages and a decreased proportion of effector T cells. Gene set enrichment analysis (GSEA) further indicated the activation of epithelial-mesenchymal transition (EMT) pathways.
Conclusions
High levels of microbiota within melanoma tissues are correlated with poor overall survival and may facilitate tumor immune evasion and metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1064P - Optimizing infusion rates of monoclonal antibodies to save time for oncology day care and patients
Presenter: Elisabeth Cornelia Suzanne de Boer
Session: Poster session 04
1065P - Dose dependent detrimental effect of baseline pantoprazole on clinical outcomes from first-line chemo-ICI regimens in patients with advanced stage NSCLC
Presenter: Leonardo Brunetti
Session: Poster session 04
1066P - Potential effects of olanzapine: Enhancing the immune response to PD-1/PD-L1 inhibitors
Presenter: yan ling Yi
Session: Poster session 04
Resources:
Abstract
1068P - Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate)
Presenter: Arielle Elkrief
Session: Poster session 04
1069TiP - A phase I/IIa dose escalation and expansion study of 23ME-01473, an anti-ULBP6/2/5 antibody, for patients with advanced solid malignancies
Presenter: Manish Sharma
Session: Poster session 04
1070TiP - A phase Ia/Ib dose-escalation/expansion study of NPX887 in subjects with solid tumor malignancies known to express HHLA2/B7-H7
Presenter: Haiying Cheng
Session: Poster session 04
1071TiP - Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors
Presenter: Reinhard Dummer
Session: Poster session 04
1073TiP - A phase I/IIa first in-human phase I study of BI 1910, a monoclonal antibody agonistic to TNFR2, as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors
Presenter: Tatiana Hernandez Guerrero
Session: Poster session 04